Orbimed Advisors LLC Pro Qr Therapeutics N.V. Transaction History

Orbimed Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$5.76 - $9.44 $7.96 Million - $13.1 Million	-1,382,502 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$9.1 - $15.55 $5.46 Million - $9.32 Million	-599,529 Reduced 30.25%	1,382,502 $12.6 Million
Q1 2019 May 15, 2019	BUY	$12.5 - $18.48 $6.8 Million - $10.1 Million	544,300 Added 37.86%	1,982,031 $27.5 Million
Q4 2018 Feb 14, 2019	SELL	$15.25 - $22.4 $9.15 Million - $13.4 Million	-600,144 Reduced 29.45%	1,437,731 $22.7 Million
Q3 2018 Nov 14, 2018	BUY	$6.45 - $21.6 $4.74 Million - $15.9 Million	734,920 Added 56.4%	2,037,875 $39.4 Million
Q4 2017 Feb 14, 2018	SELL	$2.8 - $4.8 $2.78 Million - $4.76 Million	-992,391 Reduced 43.23%	1,302,955 $4.2 Million
Q3 2017 Nov 14, 2017	BUY	$4.35 - $6.45 $9.98 Million - $14.8 Million	2,295,346	2,295,346 $11.1 Million

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $185M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.